Scancell (LON:SCLP) Trading Up 7% on Insider Buying Activity

Scancell Holdings plc (LON:SCLP) was up 7% on Wednesday after an insider bought additional shares in the company. The company traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). Approximately 1,065,551 shares traded hands during trading, an increase of 21% from the average daily volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.12).

Specifically, insider Martin Diggle purchased 44,944 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The shares were purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,424.38).

Scancell Price Performance

The company’s 50 day moving average is GBX 9.35 and its 200 day moving average is GBX 10.24. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The stock has a market capitalization of £102.54 million, a price-to-earnings ratio of -15.18 and a beta of 0.35.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.